Scientists are trying a revolutionary new approach to treat rheumatoid arthritis, multiple sclerosis, lupus and other ...

Health officials hope testing and monitoring wastewater samples could help predict - and prevent - drug overdoses in the ...

Eli Lilly and Co (NYSE:LLY) shares are trading higher on Friday. The company plans to start selling its obesity drug through ...

A new daily pill reduced bad cholesterol by 60% in a groundbreaking study of 303 adults with a genetic condition, offering ...

The New Orleans Drug Enforcement Administration reports two Mexican cartels are responsible for flooding the New Orleans area ...

Most folks with genetics that put them at risk for high cholesterol and early heart disease aren't aware of their danger, a ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Orforglipron is Lilly’s oral GLP-1 in phase 3 development as a treatment for diabetes and obesity. The FDA is expected to approve the drug in March 2026. Lilly’s November news release states that the ...

Eli Lilly becomes the first healthcare firm to hit $1T, powered by GLP-1 dominance, surging sales, and strong investor ...

Drugmaker Eli Lilly is rolling out a new model to make it easier for employers to provide access to its GLP-1 drugs for ...

Common health problems of old age -- dehydration, delirium, malnutrition or falls -- can become catastrophic following a ...